EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
...
RABBIT ANTI D-TYROSINE CONJUGATE...
... Spots and complementary RNA Spikes for the ... for glass array printing and for protocol ... cDNA labeling, hybridization stringency and background. Normalize ... Spots and Oligo Spots, and complementary RNA ...
Biology Products:(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused on ... for cardiovascular and muscle disease, today announced the ... a crucial role in the progression of amyotrophic ... in neuromuscular synaptic regeneration in mice. The ... the journal Science , reveal miR-206 as ...
(Date:12/11/2009)... MA (12/11/2009) Boston College researchers have observed the ... first time and successfully harvested the elusive charges using ... solar power efficiency, the authors report in the current ... When light is captured in solar cells, it generates ... in order to snare these charges, the electrons must ...
(Date:12/11/2009)... 11 Algeta ASA (OSE: ALGETA), ... clinical center in the,US, the Tulane Cancer ... the phase III clinical study of Alpharadin ... prostate cancer,(CRPC) that has metastasized to the ... ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) study ...
(Date:12/11/2009)... Dec. 11 Gwathmey, Inc., a ... in cancer, staph aureus, and cardiovascular disease announces ... announced today that Rosalie Dunn, Ph.D., has joined ... has over 28 years of experience working with ... to joining Gwathmey, Dr. Dunn managed multimillion dollar ...
Breaking Biology Technology:miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Elusive 'hot' electrons captured in ultra-thin solar cells 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2Biology NavigationMedical Navigation